Navigation Links
ALPCO Announces the Launch of Rat and Mouse Proinsulin ELISA Kits
Date:1/26/2010

SALEM, N.H., Jan. 26 /PRNewswire/ -- ALPCO Diagnostics has developed two new low-sample volume ELISAs for the quantitative analysis of total proinsulin (I and II) in rats and mice.  These methods were developed using synthetic rat and mouse proinsulin I and II expressed in bacteria and purified from inclusion bodies, and were first introduced in an abstract presented at the Upper Midwest Islet Club Meeting in June 2009.

Both the Rat Proinsulin ELISA and Mouse Proinsulin ELISA allow for the direct quantification of total proinsulin (I & II) in serum.  Each kit requires only 10 microlitres of serum, giving researchers the opportunity to measure multiple analytes from a single sample collection.  The evaluation of a representative sample population of commonly used mouse and rat strains showed that > 90% of samples fell within the dynamic range of the respective assays, illustrating their utility in the field.  

A hallmark of these new assay systems are their defined cross reactivity with both proinsulin I and II.  Peter Wunderli, PhD, Laboratory Operations Manager at ALPCO, remarks on the significance of this advancement, "Rat proinsulin, as for mouse, is expressed as two isoforms. No one knows whether isoform expression is individually influenced by the disease.  Until that is established, there is a need to be able to measure the total proinsulin.  Our kits do that with excellent specificity and robustness."  

Several factors, not the least of which being the variability in expression of proinsulin I and II between mice and rats, makes the ALPCO species-specific assay kits the most attractive option for researchers expecting to quantify total proinsulin in their pre-clinical models.

While research has established that the total ratio of circulating proinsulin relative to insulin and c-peptide is altered in the diabetic and pre-diabetic state in humans, multiple barriers in the ability to accurately measure rodent proinsulin means relatively limited data has been available regarding concentrations of this molecule in rats and mice, both of which are widely used models in the diabetes research community.  

Craig LaMarca, a scientist and technical sales advisor with ALPCO, stated: "Typically in humans, proinsulin is elevated as a result of impaired processing in the beta cell, which is a characteristic of type 2 diabetes.  In cases of beta cell dysfunction, including type 2 diabetes and pre-diabetes, the proinsulin secretion ratio can increase to >60% (from 5% in a non-diabetic state).  Until now, there has not been a viable method for measuring rodent proinsulin, which would allow researchers to establish models for testing targeted therapies or interventions in the pre-clinical setting.  This new ELISA will open doors for a number of basic science research studies."  Dr. Wunderli added, "While these assays are exclusively for research use, ALPCO's development process addresses the diabetes research community's need for quality and consistency, which is necessary to ensure that the data can be applied to animal studies aimed at both aiding our understanding of the disease etiology and the effectiveness of experimental treatments. 

ALPCO has been manufacturing and distributing robust, well-characterized and user-friendly ELISA methods tailored to meet the unique demands of the metabolic disease research community since 1990.  

Contact: Kate Kaplan, 800-592-5726

SOURCE ALPCO

RELATED LINKS
http://www.alpco.com

'/>"/>

SOURCE ALPCO
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. ALPCO Launches GLP-1 (Active 7-36) and (7-36 and 9-36) ELISA Kits
2. Roxane Laboratories, Inc. Announces the New Drug Application Approval of Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL)
3. Brean Murray, Carret & Co. Announces 2010 Healthcare 1x1 Conference
4. MDS Announces Resolution of Litigation Related to the Sale of MDS Analytical Technologies
5. Agilux Laboratories Announces the Launch of GLP LC/MS/MS Bioanalytical Services
6. ORCS Web, Inc Announces Plans for Employee Ownership
7. Eyre Bus, Tour & Travel Donates Bus to Transport Medical Professionals from D.C. Area to New York for Flight to Haiti, Announces the Greater Washington Haiti Relief Committee and the Embassy of Haiti
8. Forterus Announces Fiscal Year 2009 Financial Results
9. UCLB announces new partnership with Kurma Biofund
10. AXIOM Systems, Inc. Announces General Release of HIPAA 5010 Testing Solutions
11. Universal Health Services, Inc. Announces Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
Breaking Medicine Technology: